PGCM
DSGN icon

Prescott Group Capital Management’s Design Therapeutics DSGN Stock Holding History

Prescott Group Capital Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-343,000
Closed -$1.85M – 249
2024
Q3 		$1.85M Hold
343,000
– – 0.27% 115
2024
Q2 		$1.15M Hold
343,000
– – 0.18% 150
2024
Q1 		$1.38M Hold
343,000
– – 0.22% 128
2023
Q4 		$909K Buy
343,000
+163,000
+91% +$373K 0.16% 135
2023
Q3 		$425K Buy
+180,000
New +$840K 0.09% 150

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Prescott Group Capital Management's DSGN Position: Q4 2024 in Review

Prescott Group Capital Management sold out of Design Therapeutics (DSGN) in Q4 2024, closing a stake of 343,000 shares — an estimated $1.85M sold.

Prescott Group Capital Management first reported a position in DSGN in Q3 2023 and held it in 5 quarters. The position peaked at $1.85M in Q3 2024. 95 funds tracked by Wall St. Rank hold DSGN as of Q4 2024.

  • Prescott Group Capital Management reported no remaining Design Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Prescott Group Capital Management sold 343,000 Design Therapeutics shares in Q4 2024, an estimated $1.85M.
  • Prescott Group Capital Management first reported a position in Design Therapeutics in Q3 2023 and held it in 5 quarters.
  • Prescott Group Capital Management's Design Therapeutics position peaked at $1.85M in Q3 2024.
  • 95 funds tracked by Wall St. Rank held Design Therapeutics as of Q4 2024.

Based on Prescott Group Capital Management's 13F filing for Q4 2024, filed 7 Feb 2025.